bacosides – Ayurved Healing

Brahmi vs Shankhpushpi: Which Nootropic Herb Is Right for You?

Dr. Meera Iyer — Sat, 21 Feb 2026 16:47:30 +0000

Two Herbs, One Question: Which Ayurvedic Cognitive Herb Fits the Need?

“Brain tonic” is too broad for a precise Ayurvedic choice. Poor retention, stress-related distractibility, disturbed sleep, mental fatigue, and progressive cognitive change are not interchangeable complaints. Brahmi and Shankhapushpi are both described as medhya in authoritative Ayurvedic sources, but their botanical identities, classical attributes, doses, and levels of modern clinical study differ substantially.

A second distinction is essential. The well-known passage in Charaka Samhita, Chikitsa Sthana 1/3/30–31, names Mandukaparni juice, Yashtimadhu powder with milk, Guduchi juice, and Shankhapushpi paste as especially intellect-promoting rasayanas. Bacopa monnieri is not one of the four drugs named in that passage. Nevertheless, the Ayurvedic Pharmacopoeia of India separately identifies Bacopa monnieri as Brahmi and assigns it the actions medhya and rasayana. Both herbs therefore have authentic Ayurvedic standing, but not through the same textual statement.

Brahmi (Bacopa monnieri): The Better-Studied Option for Memory

The Ayurvedic Pharmacopoeia of India defines Brahmi as the dried whole plant of Bacopa monnieri (Linn.) Wettst. Modern products may contain whole-plant powder or extracts standardized to selected saponins; these forms are not dose-equivalent and should not be treated as interchangeable.

Classical Ayurvedic Profile

Its recorded pharmacopoeial attributes are:

Rasa: madhura, tikta, kashaya — sweet, bitter, and astringent
Guna: laghu and sara — light and mobile or flowing
Virya: shita — cooling
Vipaka: madhura — sweet post-digestive effect
Karma: includes medhya, rasayana, matiprada, Vatahara, and Kaphahara

The pharmacopoeia lists Sarasvatarishta, Brahmi Ghrita, Brahmi Vati, Sarasvata Churna, and Smritisagara Rasa among important formulations associated with Brahmi. Raw herb, extract capsules, and compound formulations remain therapeutically distinct.

Human Clinical Evidence

Bacopa has a larger human evidence base than Convolvulus pluricaulis. A 2001 randomized, double-blind, placebo-controlled trial of a standardized extract reported improvements after 12 weeks in visual information-processing speed, learning rate, memory consolidation, and state anxiety. A separate 2002 trial in adults aged 40–65 found a significant effect on retention of newly learned word pairs, with the pattern suggesting reduced forgetting rather than a broad improvement across every memory measure.

A 2012 systematic review found the most consistent signal in memory free recall, while effects in other cognitive domains were less consistent. A 2014 meta-analysis of randomized controlled trials concluded that Bacopa had potential cognitive benefits, particularly for speed of attention, while also calling for larger and better-designed trials. Standardized Bacopa extracts may improve selected outcomes in some adults after repeated use, but they are not established dementia treatments or universal remedies for poor concentration.

More recent evidence also argues against certainty. A 12-week randomized trial published in 2025 found no greater improvement in cognitive performance than placebo, although it reported signals for reduced stress and fatigue. Differences among extracts and study designs make product-specific interpretation important.

What Is Known About Mechanism

Bacopa contains dammarane-type triterpenoid saponins commonly grouped under the term bacosides. Laboratory and animal studies have examined antioxidant activity, cholinergic signaling, monoamine systems, synaptic plasticity, and neuroprotective pathways. Some human studies have also measured acetylcholinesterase-related outcomes. These findings do not justify equating Bacopa with donepezil or reducing its effects to one neurotransmitter pathway.

Shankhapushpi (Convolvulus pluricaulis): Classical Medhya Rasayana with Limited Human Data

The Ayurvedic Pharmacopoeia of India defines Shankhapushpi as the whole plant of Convolvulus pluricaulis Choisy. It also notes that Clitoria ternatea and Evolvulus alsinoides are used as Shankhapushpi in some parts of India. A label carrying the common name “Shankhpushpi” may therefore contain a different species from the one used in a study or monograph.

Classical Ayurvedic Profile

For pharmacopoeial Convolvulus pluricaulis, the recorded Ayurvedic attributes are:

Rasa: tikta, kashaya — bitter and astringent
Guna: sara — mobile or flowing
Virya: shita — cooling
Vipaka: madhura — sweet post-digestive effect
Karma: includes medhya, rasayana, balya, ayushya, Kaphahara, Pittahara, and mohanashaka

Charaka’s medhya-rasayana passage specifies Shankhapushpi in paste form. The pharmacopoeia lists Brahmi Ghrita, Agastyaharitaki Rasayana, Brahma Rasayana, Manasamitra Vataka, Gorocanadi Vati, and Brahmi Vati among important formulations associated with Shankhapushpi. A formulation name containing “Brahmi” does not establish that every modern product contains both herbs.

Experimental Evidence and Its Limits

Animal studies have reported memory-related, anxiolytic, and central nervous system depressant effects from Convolvulus pluricaulis extracts. A 2011 study evaluated several extracts in rodents and found activity in learning, memory, anxiety, and locomotor models, with results varying by extract and dose. Phytochemical investigations describe alkaloids, coumarins, flavonoids, and sterols, with profiles varying by material and extraction method.

Human clinical evidence for authenticated Convolvulus pluricaulis remains sparse. It is therefore inaccurate to assign it a proven four-to-six-week onset, a validated GABA mechanism in patients, or superiority over Bacopa for anxiety. Its contemporary use is best framed as a classical Ayurvedic choice requiring individualized prescribing, not a standardized nootropic protocol.

Head-to-Head Comparison

No robust direct human trial establishes that one of these herbs is categorically superior to the other. A useful comparison separates classical pharmacopoeial information from modern clinical evidence.

Parameter	Brahmi (Bacopa monnieri)	Shankhapushpi (Convolvulus pluricaulis)
Official drug part	Dried whole plant	Whole plant
Classical standing	Medhya and rasayana in the API monograph	One of Charaka’s four specified medhya rasayanas; also medhya and rasayana in the API
Rasa	Madhura, tikta, kashaya	Tikta, kashaya
Guna	Laghu, sara	Sara
Virya	Shita	Shita
Vipaka	Madhura	Madhura
Dosha-related API karma	Vatahara and Kaphahara are listed	Kaphahara and Pittahara are listed
API powder dose	1–3 g	3–8 g
Modern evidence	Several small human trials and systematic reviews; outcomes are mixed	Mainly animal and laboratory studies; limited authenticated human data
Common practical issue	Extract strengths and bacoside specifications differ	Several botanical species may be sold under the same common name

Clinical Decision Framework

Ayurvedic selection should consider the person, the complaint, digestive tolerance, concurrent medicines, and the exact preparation. Constitution alone is insufficient, and neither herb should be chosen solely from an online dosha quiz.

When Brahmi May Be the More Defensible Starting Point

Brahmi is the more evidence-supported option when the goal is a time-limited trial for memory retention or selected attention outcomes in an otherwise medically assessed adult. Considerations include:

Difficulty retaining newly learned information without sudden or progressive neurological symptoms
A preference for a product standardized in the same way as a published human trial
Willingness to use it consistently for the trial period rather than expecting an immediate stimulant effect
Access to professional review of gastrointestinal tolerance, thyroid status, and possible medicine interactions

When Shankhapushpi May Be Considered

Shankhapushpi may be selected within an Ayurvedic plan when its classical medhya, rasayana, Pittahara, and Kaphahara profile fits the assessed presentation. Practical requirements are:

Confirmation that the product contains Convolvulus pluricaulis rather than an unspecified substitute
Use of the whole herb or a clearly characterized preparation rather than assuming all syrups are equivalent
Practitioner supervision when the complaint includes anxiety, insomnia, seizures, thyroid disease, or regular medication use
Realistic expectations, because a clinically validated onset time and comparative superiority have not been established

Should They Be Combined?

A combination is not automatically more effective. Classical and proprietary formulations may contain multiple medhya herbs, but their rationale, proportions, processing, and adjuvants are formulation-specific. A fixed schedule of 300 mg Bacopa extract plus 3 g Shankhapushpi is neither a universal classical protocol nor a validated combined regimen. Combination use should follow a qualified practitioner’s assessment.

Dosing and Dosage Forms

Dose must be tied to the exact material. A gram dose of whole-plant powder cannot be converted directly into a milligram dose of concentrated extract, and commercial syrups may also contain several ingredients.

Brahmi

The Ayurvedic Pharmacopoeia of India gives 1–3 g of the drug in powder form. Several adult cognition trials used about 300 mg daily of a particular standardized extract, but the extract specification is part of the dose and cannot be omitted. Brahmi Ghrita is an official classical formulation associated with the herb; its dose should follow the applicable formulary, product directions, and practitioner advice rather than being inferred from raw-herb dosing.

Shankhapushpi

The pharmacopoeial dose is 3–8 g of the drug in powder form. It does not establish a universal dose for juice, syrup, tablets, or concentrated extracts. Because several species circulate under the common name, check the botanical name and plant part.

Ghee, Milk, and Black Pepper

Ghee has an established place in Ayurvedic dietetics and in classical medicated-ghee formulations used for medhya purposes. That use does not prove that ghee increases absorption of every constituent in either herb. Likewise, adding black pepper is not automatically appropriate; piperine can alter drug metabolism, and no universal Brahmi–Shankhapushpi protocol requires it.

Safety Considerations and Interactions

“Natural” does not mean interaction-free. Product authentication, dose, duration, age, pregnancy status, medical conditions, and concurrent medicines all affect safety.

Brahmi: Human trials most often report gastrointestinal effects such as increased stool frequency, abdominal cramps, and nausea. Caution is appropriate with thyroid disease or thyroid hormone, cholinergic or anticholinergic medicines, and drugs affected by CYP enzymes.
Shankhapushpi: Human safety and interaction data for authenticated Convolvulus pluricaulis are limited. Do not use animal thyroid findings to alter levothyroxine, antithyroid medicine, or endocrine care.
Pregnancy and breastfeeding: Avoid self-prescribing either herb because adequate human safety data and product consistency are lacking.
Children and older adults: Dosing should be individualized by a qualified Ayurvedic practitioner or healthcare professional, especially when other medicines are used.
Persistent symptoms: New, worsening, or progressive memory change, confusion, severe anxiety, sleep disruption, or functional decline requires medical evaluation rather than treatment with a nootropic supplement alone.

Consult a qualified Ayurvedic practitioner and the relevant healthcare provider before starting either herb, particularly if you are pregnant, breastfeeding, treating a thyroid or neurological condition, or taking prescription medication.

Bottom Line

Brahmi and Shankhapushpi are not interchangeable “brain herbs.” Bacopa monnieri has the stronger human research base for selected memory and attention outcomes, although results are mixed and extract-specific. Convolvulus pluricaulis has a particularly clear classical position as one of Charaka’s medhya rasayanas, but its modern human evidence is much thinner and botanical substitution is a major practical concern. The sound choice depends on authenticated material, the precise clinical goal, the Ayurvedic assessment, and safety review—not on claims of a universal best nootropic.

References

Brahmi for Memory: What the Latest Clinical Trials Actually Found

Dr. Meera Iyer — Thu, 19 Feb 2026 07:30:00 +0000

A well-designed trial can be useful even when its primary outcome is negative. The 2025 Bacumen trial is a good example. It tested whether a defined Bacopa monnieri extract could improve cognition in middle-aged and older adults, while also measuring stress, fatigue, mood, and selected blood markers.

The randomized, double-blind, placebo-controlled study enrolled 101 adults aged 40 to 70 who reported memory and attention problems. Participants received either 300 mg of Bacumen extract daily or placebo for 12 weeks. Eighty-seven participants completed the trial.

The principal result was clear: compared with placebo, the extract did not produce significantly greater improvement in verbal learning, attention, or working memory. The trial therefore does not support presenting this preparation, at this dose and duration, as a dependable memory enhancer for this population.

The same study also reported greater reductions in self-rated stress reactivity and in fatigue and stress after a cognitively demanding task. These were secondary outcomes, so they should be treated as signals for further investigation rather than proof of a general anti-stress or anti-fatigue effect.

What the Bacumen Trial Actually Found

The study’s primary cognitive measures were verbal learning, attention, and working memory. The between-group results were not significant for any of them. Blood concentrations of brain-derived neurotrophic factor, malondialdehyde, and acetylcholinesterase activity also did not differ between groups after treatment.

The secondary findings were more favorable. Participants taking Bacopa reported a greater reduction in overall stress reactivity, together with lower fatigue and stress after a demanding computer task. The authors concluded that these effects require confirmation in future trials.

The safety findings also matter. No serious adverse reaction was reported, but the Bacopa group had more self-reported adverse reactions than the placebo group, mainly digestive complaints and headaches. The study was funded by the supplier of the tested product, although the published declaration states that the sponsor was not involved in data collection, interpretation, or the decision to submit the paper.

This combination of negative primary outcomes and positive secondary outcomes calls for restraint. It does not justify saying that Brahmi “failed,” but it also does not justify converting stress and fatigue findings into a memory claim. The most accurate conclusion is that this particular trial did not demonstrate cognitive enhancement and identified secondary signals that need replication.

How This Fits the Earlier Human Evidence

Earlier reviews have found limited but potentially meaningful cognitive signals. A 2014 meta-analysis of nine randomized controlled trials involving 437 participants concluded that Bacopa monnieri had potential to improve cognition, particularly the speed of attention. A 2012 systematic review found some support for improved memory free recall, while results for other cognitive abilities were less consistent.

Individual trials have also reported benefits in delayed recall, memory acquisition, or selected attention tasks. Other trials have produced null or mixed findings. Taken together, the human literature is not a single, uniform body of evidence: preparations, bacoside assays, participant characteristics, outcome tests, doses, and treatment periods vary substantially.

This variation explains why a positive result from one extract cannot automatically be transferred to every Brahmi powder, capsule, syrup, or proprietary preparation. Botanical identity is only the first requirement. Extraction method, plant part, extract ratio, chemical standardization, storage, dose, adherence, and the population being treated can all affect the relevance of a trial to a commercial product.

Population and Baseline Status

The Bacumen participants were not diagnosed with dementia or another cognitive disorder. They were adults with self-reported memory and attention problems. That distinction is important because results in healthy adults, people with subjective complaints, people with mild cognitive impairment, and people with dementia answer different clinical questions.

It is therefore too speculative to attribute the null result to a “ceiling effect” or to claim that Brahmi works mainly when a deficit is present. Some studies in older adults or people with cognitive complaints have reported favorable outcomes, but the available trials do not establish a dependable rule about which subgroup will respond.

Dose, Duration, and Standardization

The Bacumen trial used 300 mg daily for 12 weeks. Clinical references commonly describe adult extract doses in the range of 300 to 450 mg daily, and many cognition trials have lasted about 12 weeks. These figures describe research protocols; they are not a universal prescription and do not establish an optimal dose.

The claim that every effective extract must contain at least 50% bacosides is inaccurate. Clinical products have used different assays and standardization levels, and clinical references describe extracts standardized within a broader 24% to 55% bacoside range. The label should identify the botanical, plant part, extract ratio or solvent where applicable, and the method or marker used for standardization.

There is likewise no established requirement that bacosides must “accumulate in neural tissue” for eight to twelve weeks. Longer administration may be used because several cognitive trials were designed over that period, but the optimal frequency, dose, duration, bioavailability, and pharmacokinetics remain unsettled.

The Ayurvedic Identity of Brahmi

The Ayurvedic Pharmacopoeia of India identifies Brāhmī as Bacopa monnieri (Linn.) Wettst. in its official monograph and also provides a later monograph for the whole plant. This pharmacopoeial identity is the appropriate starting point when an article or product specifically refers to Bacopa Brahmi.

Nomenclature requires care because “Brahmi” has also been used regionally for Centella asiatica, commonly called Maṇḍūkaparṇī. The two plants are botanically distinct and should not be treated as interchangeable merely because some traditional and commercial naming overlaps.

In Ayurvedic practice, Brahmi is placed within a broader approach to medhā, mental steadiness, learning, recollection, and rejuvenative care. An Ayurvedic prescription is not determined by a single modern outcome such as a memory-test score. The practitioner considers the person’s constitution, current imbalance, age, strength, digestion, sleep, mental state, preparation, dose, vehicle, season, diet, and accompanying medicines.

That context does not cancel the need for clinical testing. It explains why traditional use and a standardized-extract trial are related but not identical questions. The trial evaluates a defined product under a defined protocol; Ayurvedic treatment may employ different dosage forms and individualized combinations under professional supervision.

Neuroprotection and Disease Claims

Bacopa contains triterpenoid saponins collectively described as bacosides. Laboratory and animal work has examined antioxidant activity, inflammatory signaling, cholinergic pathways, mitochondrial function, amyloid-beta aggregation, and tau-related processes. These mechanisms are scientifically interesting, but most disease-oriented findings remain preclinical.

A 2025 review in Nutrients summarized possible roles in Alzheimer-related pathways, including oxidative stress, neuroinflammation, mitochondrial dysfunction, amyloid-beta toxicity, and tau biology. A mechanistic review can identify plausible targets; it cannot by itself establish that a supplement prevents, slows, or treats Alzheimer disease.

The clinical distinction is reinforced by a systematic review of randomized trials in Alzheimer disease or mild cognitive impairment. It identified five eligible trials, judged the certainty of the evidence very low, and found no established difference between Bacopa and placebo or donepezil. The trials were small and heterogeneous, with variation in diagnosis, formulations, treatment duration, and cognitive outcomes.

Brahmi should therefore not replace medical assessment or prescribed treatment for memory loss, mild cognitive impairment, dementia, schizophrenia, epilepsy, anxiety disorders, or any other neurological or psychiatric condition. New or progressive forgetfulness, disorientation, personality change, seizures, severe headache, weakness, speech difficulty, or loss of daily functioning requires prompt clinical evaluation.

A Balanced Assessment

The most defensible position lies between dismissal and marketing exaggeration. Bacopa has an authentic place in Ayurveda, a pharmacopoeially recognized botanical identity, and a body of human research with some positive cognitive and stress-related findings. It also has inconsistent results, product variability, short trials, and unresolved questions about optimal use.

Reasonably supported conclusions include:

Some randomized trials and pooled analyses have reported improvements in speed of attention, free recall, delayed recall, or memory acquisition.
The 2025 Bacumen trial did not improve its primary cognitive outcomes compared with placebo.
The same trial reported secondary reductions in self-rated stress reactivity and task-related fatigue and stress.
Digestive symptoms are the most frequently described adverse effects, and headache has also been reported.

Claims that are not established include:

That Brahmi reliably makes every healthy person remember more or think faster.
That a 50% bacoside assay is the universal minimum for an effective product.
That eight to twelve weeks are required because bacosides accumulate in brain tissue.
That Bacopa prevents or treats Alzheimer disease or can substitute for donepezil or other prescribed care.
That one dosage or extract specification is appropriate for all ages, constitutions, conditions, and medicines.

Important uncertainties remain:

The most useful dose, duration, extract, and outcome measures for different populations.
The clinical relevance of stress and fatigue changes to everyday cognition.
How standardized extracts compare with powders, fresh juice, ghṛta, or compound Ayurvedic formulations.
Safety during prolonged use and the practical significance of possible herb-drug interactions.

Practical Use and Product Quality

Published protocols can guide interpretation, but they should not be converted into a universal self-treatment schedule. Product chemistry varies, and a milligram amount is meaningful only when the extract and its standardization are clearly described.

Parameter	Evidence-based interpretation
Botanical identity	Look for Bacopa monnieri; the Ayurvedic Pharmacopoeia of India recognizes Brāhmī under this botanical name.
Plant material	The label should state the plant part or whole plant and distinguish Bacopa from Centella asiatica.
Extract dose	Adult trials often use about 300–450 mg daily, but the appropriate dose depends on the specific extract, person, condition, and clinician’s advice.
Standardization	Products vary; 50% bacosides is not a universal benchmark. The assay and amount per serving should be stated.
Trial duration	Many cognition studies last approximately 12 weeks; the optimal duration and long-term safety are not established.
Common adverse effects	Nausea, abdominal cramps, increased stool frequency, other digestive complaints, and headache may occur.

Safety and consultation: Consult a qualified Ayurvedic practitioner and your healthcare provider before using Brahmi medicinally, especially when taking prescription medicines. Bacopa may have cholinergic effects, may inhibit several CYP450 enzymes in laboratory testing, and warrants caution with thyroid treatment and medicines whose effects could be altered by these pathways. People who are pregnant or breastfeeding, children, and those with bradycardia, thyroid disease, peptic ulcer disease, bowel or urinary obstruction, asthma, COPD, or complex neurological or psychiatric conditions should use it only under qualified clinical guidance.

Stop the product and seek medical advice if troublesome vomiting, diarrhea, abdominal pain, rash, marked dizziness, unusual sedation, palpitations, sweating, or other unexpected symptoms occur. Every herb and supplement should be disclosed during medication review.

What the Trial Changes

The Bacumen trial narrows the claim that can responsibly be made. It does not support a straightforward promise of better verbal learning, attention, or working memory after 12 weeks of 300 mg daily in adults aged 40 to 70 with subjective memory and attention problems.

It provides a reason to examine stress reactivity and fatigue more closely in future, adequately powered trials that predefine these outcomes and use independently verified extracts. Replication is especially important because secondary outcomes are more vulnerable to chance findings and because different Bacopa preparations cannot be assumed to be equivalent.

For Ayurveda, the useful lesson is not that traditional knowledge must be exempt from testing, nor that one negative trial erases traditional use. It is that identity, preparation, person, indication, outcome, and safety must all be stated precisely. Brahmi is better understood as an Ayurvedic medicinal plant with a mixed and still-developing clinical evidence base—not as a guaranteed memory pill and not as a treatment for neurodegenerative disease.